JPMorgan Chase & Co. Purchases 2,643 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ)

JPMorgan Chase & Co. boosted its holdings in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) by 46.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,342 shares of the company’s stock after purchasing an additional 2,643 shares during the period. JPMorgan Chase & Co.’s holdings in LENZ Therapeutics were worth $241,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of LENZ. Vanguard Group Inc. lifted its position in shares of LENZ Therapeutics by 5.3% during the 4th quarter. Vanguard Group Inc. now owns 1,178,447 shares of the company’s stock worth $34,022,000 after buying an additional 59,630 shares during the last quarter. Harbor Capital Advisors Inc. bought a new position in shares of LENZ Therapeutics in the fourth quarter worth about $1,270,000. Swiss National Bank acquired a new stake in shares of LENZ Therapeutics in the 4th quarter valued at approximately $546,000. Barclays PLC grew its holdings in shares of LENZ Therapeutics by 273.1% during the 3rd quarter. Barclays PLC now owns 16,463 shares of the company’s stock valued at $391,000 after purchasing an additional 12,051 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in LENZ Therapeutics during the 3rd quarter worth approximately $286,000. Institutional investors and hedge funds own 54.32% of the company’s stock.

LENZ Therapeutics Stock Up 2.2 %

Shares of NASDAQ:LENZ opened at $29.52 on Friday. The firm has a market cap of $813.07 million, a P/E ratio of -6.19 and a beta of 0.43. LENZ Therapeutics, Inc. has a 12-month low of $14.42 and a 12-month high of $38.93. The business has a fifty day simple moving average of $24.07 and a 200 day simple moving average of $27.28.

LENZ Therapeutics (NASDAQ:LENZ) last posted its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04). As a group, equities research analysts expect that LENZ Therapeutics, Inc. will post -2.18 EPS for the current year.

Analysts Set New Price Targets

LENZ has been the topic of a number of research analyst reports. Piper Sandler initiated coverage on shares of LENZ Therapeutics in a research report on Monday, April 14th. They issued an “overweight” rating and a $51.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $38.00 price objective on shares of LENZ Therapeutics in a report on Wednesday, April 16th. Citigroup upped their target price on LENZ Therapeutics from $44.00 to $47.00 and gave the stock a “buy” rating in a report on Thursday, March 20th. Finally, TD Cowen initiated coverage on LENZ Therapeutics in a research note on Tuesday, March 18th. They set a “buy” rating and a $60.00 price target on the stock. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $46.60.

LENZ Therapeutics Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.